NASDAQ:LIPO Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis $0.0005 0.00 (0.00%) As of 09/25/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC Filings About Lipella Pharmaceuticals Stock (NASDAQ:LIPO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LIPO alerts:Sign Up Key Stats Today's Range$0.0005▼$0.000550-Day Range$0.00▼$0.0352-Week Range$0.00▼$0.64Volume26 shsAverage Volume28,662 shsMarket Capitalization$2.31 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) is a clinical-stage biotechnology company focused on developing treatments for diseases with limited or inadequate therapeutic options. The company uses proprietary liposomal drug-delivery technology designed to deliver established pharmaceutical ingredients directly to affected tissues and potentially improve local treatment while reducing systemic exposure. Lipella’s development programs include LP-10, an intravesical formulation of tacrolimus being investigated for hemorrhagic cystitis, a serious bladder condition that can occur after cancer treatment. The company is also developing LP-310, a locally administered formulation intended to address oral mucositis, a painful complication associated with certain cancer therapies. Its pipeline has included additional candidates targeting inflammatory and other localized diseases. Based in Pittsburgh, Pennsylvania, Lipella conducts research and clinical development in the United States. As a development-stage pharmaceutical company, its product candidates remain subject to clinical testing and regulatory review before they can be marketed broadly.AI Generated. May Contain Errors. Read More Receive LIPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipella Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LIPO Stock News HeadlinesLipella Pharmaceuticals Begins Chapter 11 Bankruptcy Restructuring ProcessMarch 31, 2026 | tipranks.comLipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11March 30, 2026 | globenewswire.comBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing December 8th.September 28 at 1:00 AM | Paradigm Press (Ad)Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen PlanusSeptember 18, 2025 | finance.yahoo.comLipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen PlanusSeptember 15, 2025 | prnewswire.comLIPO - Lipella Pharmaceuticals Inc Ordinary Shares Dividends | MorningstarJuly 18, 2025 | morningstar.comMLipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting - MorningstarJune 27, 2025 | morningstar.comMLipella Pharmaceuticals delisted from Nasdaq, explores relisting options amid ongoing operationsJune 27, 2025 | bizjournals.comSee More Headlines LIPO Stock Analysis - Frequently Asked Questions How have LIPO shares performed this year? Lipella Pharmaceuticals' stock was trading at $0.18 on January 1st, 2026. Since then, LIPO shares have decreased by 99.7% and is now trading at $0.0005. How were Lipella Pharmaceuticals' earnings last quarter? Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) posted its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.64) earnings per share for the quarter. The business had revenue of $0.13 million for the quarter. Lipella Pharmaceuticals had a negative trailing twelve-month return on equity of 224.08% and a negative net margin of 988.83%. When did Lipella Pharmaceuticals' stock split? Lipella Pharmaceuticals's stock reverse split on the morning of Friday, November 8th 2024.A 1-8 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Lipella Pharmaceuticals IPO? Lipella Pharmaceuticals (LIPO) raised $7 million in an initial public offering on Tuesday, December 20th 2022. The company issued 1,217,391 shares at a price of $5.75-$6.25 per share. How do I buy shares of Lipella Pharmaceuticals? Shares of LIPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lipella Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lipella Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), MSP Recovery (LIFW), NVIDIA (NVDA), Heatwurx (PCSA), Energy Transfer (ET), Labor Smart (LTNC) and NIO (NIO). Company Calendar Last Earnings5/14/2025Today9/28/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LIPO CIK1347242 Weblipella.com Phone412-901-0315FaxN/AEmployees7Year Founded2005Profitability EPS (Trailing Twelve Months)($2.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.02 million Net Margins-988.83% Pretax Margin-988.63% Return on Equity-224.08% Return on Assets-172.88% Debt Debt-to-Equity RatioN/A Current Ratio6.21 Quick Ratio6.21 Sales & Book Value Annual Sales$536.36 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book0.00Miscellaneous Outstanding Shares4,621,000Free Float3,033,000Market Cap$2.31 thousand OptionableNot Optionable Beta1.57 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:LIPO) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
